Table 2.
Evaluation of immunohistochemical positivity in lung, breast, liver cancer tissues
| Per cent CD44+ cells | Per cent CD133+ cells | Per cent CD176+ cells | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer type | +* | ++ | +++ | ++++ | + | ++ | +++ | ++++ | + | ++ | +++ | ++++ |
| Lung carcinoma (NSCLC) | 0/10† | 0/10 | 0/10 | 10/10 | 11/21 | 6/21 | 1/21 | 1/21 | 5/21 | 9/21 | 3/21 | 4/21 |
| Breast carcinoma | 0/15 | 1/15 | 6/15 | 8/15 | 10/15 | 2/15 | 0/15 | 0/15 | 2/15 | 12/15 | 1/15 | 0/15 |
| Liver cancer (HCC) | 0/21 | 0/21 | 9/21 | 12/21 | 11/15 | 3/15 | 0/15 | 0/15 | 10/21 | 7/21 | 4/21 | 0/21 |
NSCLC, non-small cell lung carcinoma; HCC, hepatocellular carcinoma.
*Score: +, <5%; ++, 5–30%; +++, 30–60%; ++++, >60%.
†
No. of relevant cases /total no. of cases examined.